SI-BONE, Inc. (NASDAQ:SIBN - Get Free Report) Director Jeffrey W. Dunn sold 1,609 shares of the firm's stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $12.43, for a total transaction of $19,999.87. Following the transaction, the director now directly owns 20,431 shares of the company's stock, valued at approximately $253,957.33. This trade represents a 7.30 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
SI-BONE Trading Down 1.4 %
Shares of SIBN stock opened at $12.15 on Thursday. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22. SI-BONE, Inc. has a one year low of $11.76 and a one year high of $21.70. The company has a 50 day moving average price of $13.85 and a 200 day moving average price of $14.25.
Institutional Trading of SI-BONE
Institutional investors have recently made changes to their positions in the stock. FMR LLC boosted its holdings in SI-BONE by 103.6% in the third quarter. FMR LLC now owns 2,354 shares of the company's stock valued at $33,000 after acquiring an additional 1,198 shares during the last quarter. Canada Pension Plan Investment Board purchased a new position in shares of SI-BONE in the 2nd quarter worth about $61,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of SI-BONE by 24.7% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,649 shares of the company's stock valued at $138,000 after purchasing an additional 2,108 shares in the last quarter. Arizona State Retirement System grew its holdings in shares of SI-BONE by 9.0% during the 2nd quarter. Arizona State Retirement System now owns 10,921 shares of the company's stock worth $141,000 after purchasing an additional 903 shares during the period. Finally, Walleye Capital LLC acquired a new stake in SI-BONE during the 3rd quarter worth approximately $144,000. 98.11% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
I was wrong. Dead wrong.
From Porter & Company | Ad
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was.
Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Here’s the full story for you.
A number of equities analysts have recently weighed in on SIBN shares. Truist Financial boosted their price target on SI-BONE from $16.00 to $18.00 and gave the stock a "buy" rating in a report on Wednesday, November 13th. Needham & Company LLC reissued a "buy" rating and issued a $19.00 target price on shares of SI-BONE in a research note on Wednesday. Finally, Morgan Stanley reduced their target price on shares of SI-BONE from $21.00 to $19.00 and set an "overweight" rating on the stock in a report on Tuesday, August 6th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $23.00.
Check Out Our Latest Report on SI-BONE
SI-BONE Company Profile
(
Get Free Report)
SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
